BioLineRx (BLRX) Operating Leases (2018 - 2025)

BioLineRx's Operating Leases history runs 8 years deep, the most recent figure standing at $1.2 million for Q4 2025.

• In Q4 2025, Operating Leases rose 12.03% year-over-year to $1.2 million; the TTM figure through Dec 2025 stood at $1.2 million (up 12.03% YoY), while the FY2025 annual figure was $1.2 million, up 12.03% from the prior year.
• Operating Leases was $1.2 million for Q4 2025 at BioLineRx, up from $1.1 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $2.2 million in Q4 2022 to a low of $1.1 million in Q4 2024.
• Historically, Operating Leases has averaged $1.6 million across 5 years, with a median of $1.8 million in 2023.
• The sharpest annual moves came in 2021 and 2024: Operating Leases grew 14.03% in 2021, then plunged 40.54% in 2024.
• A 5-year view of Operating Leases shows it stood at $1.9 million in 2021, then gained by 13.83% to $2.2 million in 2022, then fell by 15.68% to $1.8 million in 2023, then slumped by 40.54% to $1.1 million in 2024, then gained by 12.03% to $1.2 million in 2025.
• The last three Operating Leases figures came in at $1.2 million (Q4 2025), $1.1 million (Q4 2024), and $1.8 million (Q4 2023), per Business Quant data.